Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
21 Marzo 2024 - 6:00AM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced that management will present a corporate overview at the
MedInvest Biotech & Pharma Investor Conference taking place in
New York City on April 3-4, 2024. Management will be available for
one-on-one meetings with investors who are registered for the
conference.
Presentation
Details: |
Date: |
Wednesday, April 3, 2024 |
Time: |
4:20 pm EST |
Webcast: |
Recording of the presentation
will be available after the event on Aspira’s IR website |
Registration: |
Click HERE to register and attend
the conference |
|
|
About MedInvest Biotech & Pharma
Investor ConferenceThis two-day conference features
presentations from more than 40 companies developing and/or
commercializing technologies across a broad spectrum of indications
– including oncology, immunology, neurology, cardiology, diabetes,
infectious, pulmonary, autoimmune, respiratory diseases, urology,
endocrinology, dermatology, pain management, and many others. The
event also will feature talks from key industry opinion leaders,
investor panel discussions, and insightful conversations with the
National Cancer Institute on patenting, facilitating
collaborations, licensing and technology analysis, and
marketing.
About Aspira Women’s Health
Inc.Aspira Women’s Health Inc. is dedicated to the
discovery, development, and commercialization of noninvasive,
AI-powered tests to aid in the diagnosis of gynecologic
diseases.
OvaWatch® and Ova1Plus® are offered to clinicians
as OvaSuiteSM. Together, they provide the only comprehensive
portfolio of blood tests to aid in the detection of ovarian cancer
for the 1.2+ million American women diagnosed with an adnexal mass
each year. OvaWatch provides a negative predictive value of 99% and
is used to assess ovarian cancer risk for women where initial
clinical assessment indicates the mass is indeterminate or benign,
and thus surgery may be premature or unnecessary. Ova1Plus is a
reflex process of two FDA-cleared tests, Ova1® and Overa®, to
assess the risk of ovarian malignancy in women planned for
surgery.
Our in-development test pipeline is designed to
expand our ovarian cancer portfolio and addresses the tremendous
need for noninvasive diagnostics for endometriosis, a debilitating
disease that impacts millions of women worldwide. In ovarian
cancer, our OvaMDxSM risk assessment is designed to combine
microRNA and protein biomarkers with patient data to further
enhance the sensitivity and specificity of our current tests. In
endometriosis, EndoCheckSM is the first-ever noninvasive test
designed to identify endometriomas, one of the most commonly
occurring forms of endometriosis. The EndoMDxSM test is designed to
combine microRNA and protein biomarkers with patient data to
identify all endometriosis.
Forward-Looking StatementsThis
press release may contain forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities
laws, including those relating to the timing and completion of any
products in the pipeline development and other statement that are
predictive in nature. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as “designed to,” “expect,”
“plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,”
“future,” other words of similar meaning and the use of future
dates. Forward-looking statements in this press release and other
factors are not guarantees of future performance and undue reliance
should not be placed on them. Such forward-looking statements
necessarily involve known and unknown risks and uncertainties,
which may cause actual performance and financial results in future
periods to differ materially from any projections of future
performance or result expressed or implied by such forward looking
statements. These and additional risks and uncertainties are
described more fully in the Company’s filings with the SEC,
including those factors identified as “risk factors” in our most
recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Q. We are providing this information as of the date of
this press release and do not undertake any obligation to update
any forward-looking statements contained in this document as a
result of new information, future events or otherwise, except as
required by law.
Investor Relations
Contact: Torsten Hombeck, Ph.D. Chief Financial
Officer Aspira Women’s HealthInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024